661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.